Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Audio By Carbonatix

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan 30, 2026--

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12, 2026 in New York.

Details of the event are as follows:
Date: Thursday, February 12, 2026
Time: 2:00p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260130979631/en/

CONTACT: Adicet Bio., Inc.

Investor and Media ContactsAnne Bowdidge

[email protected] Belnap

Precision AQ

[email protected]

KEYWORD: CALIFORNIA NEW YORK UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH HEALTH PHARMACEUTICAL ONCOLOGY

SOURCE: Adicet Bio, Inc.

Copyright Business Wire 2026.

PUB: 01/30/2026 07:00 AM/DISC: 01/30/2026 07:00 AM

http://www.businesswire.com/news/home/20260130979631/en